SC 13G/A | 2024-02-09 | FMR LLC | Poseida Therapeutics, Inc. | 14,343,665 | 15.0% | EDGAR |
SC 13G | 2024-01-31 | BlackRock Inc. | Poseida Therapeutics, Inc. | 5,031,173 | 5.3% | EDGAR |
SC 13D | 2023-08-14 | Astellas US LLC | Poseida Therapeutics, Inc. | 8,333,333 | 8.7% | EDGAR |
SC 13G/A | 2023-02-09 | FMR LLC | Poseida Therapeutics, Inc. | 12,892,407 | 15.0% | EDGAR |
SC 13D/A | 2022-04-25 | Pentwater Capital Management LP | Poseida Therapeutics, Inc. | 4,967,227 | 7.9% | EDGAR |
SC 13G/A | 2022-02-09 | FMR LLC | Poseida Therapeutics, Inc. | 9,375,941 | 15.0% | EDGAR |
SC 13G | 2021-02-12 | NOVARTIS PHARMA AG | Poseida Therapeutics, Inc. | 5,908,089 | 9.6% | EDGAR |
SC 13G/A | 2021-02-08 | FMR LLC | Poseida Therapeutics, Inc. | 9,273,001 | 15.0% | EDGAR |
SC 13G | 2021-02-03 | Malin Life Sciences Holdings Ltd | Poseida Therapeutics, Inc. | 9,188,125 | 14.9% | EDGAR |
SC 13D | 2020-12-28 | Pentwater Capital Management LP | Poseida Therapeutics, Inc. | 4,967,227 | 8.0% | EDGAR |
SC 13G | 2020-08-10 | FMR LLC | Poseida Therapeutics, Inc. | 9,272,382 | 15.0% | EDGAR |